Higher-dose Exelon Patch approved for Alzheimer's

Share this article:
Higher-dose Exelon Patch approved for Alzheimer's
Higher-dose Exelon Patch approved for Alzheimer's
The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer's disease. Approval was based on a 48-week double-blind phase of the OPTIMA study. The controlled trial targeted people with mild to moderate Alzheimer's. Compared to an older patch, patients treated with this higher dosage patch experienced statistically significant functional improvement.
Share this article:

More in Products

LeadingAge's CAST releases medication management tools

LeadingAge's Center for Aging Services Technologies release new tools last week to help long-term care providers identify the best medication management product.

Butler Mobility updates paint colors for platform lifts

Butler Mobility updates paint colors for platform lifts

Butler Mobility has widened the spectrum of paint color choices for its Incline Platform Lifts line.

NeuroMetrix releases pain management system

NeuroMetrix releases pain management system

NeuroMetrix Inc. has created the SENSUS™ Pain Management System, a wearable neurostimulation technology developed for chronic neuropathic pain, including painful diabetic neuropathy.